An Open Label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Progressing After First Line Therapy
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Futuximab/modotuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Symphogen
- 23 Jun 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated
- 17 Jan 2017 Status changed from recruiting to active, no longer recruiting.